JP2024522312A5 - - Google Patents

Info

Publication number
JP2024522312A5
JP2024522312A5 JP2023566547A JP2023566547A JP2024522312A5 JP 2024522312 A5 JP2024522312 A5 JP 2024522312A5 JP 2023566547 A JP2023566547 A JP 2023566547A JP 2023566547 A JP2023566547 A JP 2023566547A JP 2024522312 A5 JP2024522312 A5 JP 2024522312A5
Authority
JP
Japan
Prior art keywords
optionally substituted
atoms
group
linear
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/089724 external-priority patent/WO2022228493A1/zh
Publication of JP2024522312A publication Critical patent/JP2024522312A/ja
Publication of JP2024522312A5 publication Critical patent/JP2024522312A5/ja
Pending legal-status Critical Current

Links

JP2023566547A 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用 Pending JP2024522312A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110475315 2021-04-29
CN202110475315.1 2021-04-29
PCT/CN2022/089724 WO2022228493A1 (zh) 2021-04-29 2022-04-28 抗体偶联药物的制备方法及应用

Publications (2)

Publication Number Publication Date
JP2024522312A JP2024522312A (ja) 2024-06-14
JP2024522312A5 true JP2024522312A5 (cg-RX-API-DMAC10.html) 2025-04-02

Family

ID=83846703

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023566660A Pending JP2024522389A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566547A Pending JP2024522312A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用
JP2023566659A Active JP7900834B2 (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023566660A Pending JP2024522389A (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023566659A Active JP7900834B2 (ja) 2021-04-29 2022-04-28 抗体薬物複合体の調製方法および使用

Country Status (10)

Country Link
US (3) US20240238440A1 (cg-RX-API-DMAC10.html)
EP (3) EP4331612A4 (cg-RX-API-DMAC10.html)
JP (3) JP2024522389A (cg-RX-API-DMAC10.html)
KR (2) KR20240006029A (cg-RX-API-DMAC10.html)
CN (3) CN117241834A (cg-RX-API-DMAC10.html)
AU (1) AU2022263700A1 (cg-RX-API-DMAC10.html)
CA (3) CA3173758A1 (cg-RX-API-DMAC10.html)
IL (1) IL308025A (cg-RX-API-DMAC10.html)
TW (1) TW202308701A (cg-RX-API-DMAC10.html)
WO (3) WO2022228495A1 (cg-RX-API-DMAC10.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238440A1 (en) * 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
CA3266848A1 (en) 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
JP2026504840A (ja) * 2023-01-11 2026-02-10 ジェンマブ エー/エス リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法
CN122080121A (zh) * 2023-03-22 2026-05-26 映恩生物科技(上海)有限公司 连接子及其在配体药物偶联物中的应用
TW202438069A (zh) * 2023-03-30 2024-10-01 大陸商上海齊魯製藥研究中心有限公司 依喜替康衍生物及其抗體藥物偶聯物
WO2024212922A1 (zh) * 2023-04-11 2024-10-17 映恩生物制药(苏州)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
CN119300868B (zh) * 2023-05-11 2026-03-13 映恩生物科技(上海)有限公司 喜树碱类化合物及其偶联物、其制备方法和用途
EP4713020A2 (en) * 2023-05-19 2026-03-25 Solve Therapeutics, Inc. Drug-linkers and drug conjugates
WO2024250984A1 (zh) * 2023-06-07 2024-12-12 上海维申医药有限公司 一种抗体药物偶联物,及其药物组合物、制备和用途
EP4737483A1 (en) * 2023-06-30 2026-05-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate production method including purification step using activated carbon material
WO2025011419A1 (zh) 2023-07-07 2025-01-16 上海诗健生物科技有限公司 一种连接子-药物分子及抗体药物偶联物、其制备方法和应用
IL326233A (en) * 2023-08-04 2026-03-01 Shanghai Huao Co Ltd Multidrug Linker and Antibody-Drug Conjugation
IL324001A (en) * 2023-09-22 2025-12-01 Obi Pharma Inc Improved linker-payloads for antibody conjugation, pharmaceutical compositions and applications thereof
AU2024369355A1 (en) 2023-10-23 2026-05-07 Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. Camptothecin drug conjugate, and preparation method therefor and use thereof
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof
WO2025149019A1 (en) * 2024-01-12 2025-07-17 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
WO2025153092A1 (en) * 2024-01-18 2025-07-24 Beijing Joinn Biologics Co., Ltd Antibody-drug conjugate
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025209545A1 (zh) * 2024-04-03 2025-10-09 上海药明合联生物技术有限公司 用于抗体药物偶联物的连接子、其用途和由其制备的抗体药物偶联物
WO2025222052A2 (en) * 2024-04-18 2025-10-23 Solve Therapeutics, Inc. Conjugates and uses thereof
WO2025259928A1 (en) * 2024-06-13 2025-12-18 Obi Pharma, Inc. Improved trop2 conjugated biological molecules, pharmaceutical compositions and applications thereof
WO2025261478A1 (en) * 2024-06-21 2025-12-26 Biotheus Inc. Antibody drug conjugates and applications thereof
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof
WO2026037394A1 (zh) * 2024-08-16 2026-02-19 石药集团巨石生物制药有限公司 一种抗体药物偶联物及其用途
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof
WO2026067624A1 (zh) * 2024-09-27 2026-04-02 上海森辉医药有限公司 一种包含亲水基团的配体-药物偶联物及其在医药上的应用
CN119143876B (zh) * 2024-10-09 2025-09-16 武汉海沙百得生物技术有限公司 一种抗cd27l的全人源抗体或抗体片段及其应用
WO2026078443A1 (en) 2024-10-11 2026-04-16 Pheon Therapeutics Ltd. Antibody drug conjugates that bind cdcp1 and uses thereof
CN120484249B (zh) * 2025-04-29 2026-03-10 中山大学 一种含氟修饰的聚肌氨酸化脂质及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391745A (en) * 1992-07-23 1995-02-21 Sloan-Kettering Institute For Cancer Research Methods of preparation of camptothecin analogs
AU2002363658B2 (en) * 2001-11-14 2008-09-11 Rutgers, The State University Solubilized topoisomerase poisons
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
KR20210132742A (ko) * 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
GB2529356B (en) * 2013-04-28 2020-12-23 Genequantum Healthcare Co Ltd Novel linkers, coupling intermediates, conjugates, preparation method and application thereof
SG10201902571VA (en) * 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
EP3517114A1 (en) * 2014-04-29 2019-07-31 Genequantum Healthcare (Suzhou) Co., Ltd. New stable antibody-drug conjugate, preparation method and use thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
EP3347048B1 (en) 2015-09-09 2020-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
TWI926682B (zh) 2017-05-15 2026-05-21 日商第一三共股份有限公司 抗體-藥物結合物之製造方法
EP3700577A1 (en) 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
EP3790590A1 (en) 2018-05-10 2021-03-17 CIS Pharma AG Biocompatible copolymer containing multiple active agent molecules
CA3140063A1 (en) * 2019-05-20 2020-11-26 Novartis Ag Antibody drug conjugates having linkers comprising hydrophilic groups
CA3085001C (en) 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
US20240238440A1 (en) * 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
AU2022406708A1 (en) * 2021-12-10 2024-06-27 Multitude Therapeutics Inc. Anti-cdh6 antibodies and antibody-drug conjugates thereof
CA3266848A1 (en) * 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof

Similar Documents

Publication Publication Date Title
JP2024522388A5 (cg-RX-API-DMAC10.html)
JP2024522389A5 (cg-RX-API-DMAC10.html)
CN103483236B (zh) 制备5-联苯-4-基-2-甲基戊酸衍生物的方法和中间体
AU603999B2 (en) Porphyrin derivatives, and their production and use
CN103080072B (zh) 制备可用于生产nep抑制剂的中间体的新方法
US5262532A (en) Paramagnetic metalloporphyrins as contrast agents for magnetic resonance imaging
US6111107A (en) High yield method for stereoselective acylation of tertiary alcohols
JP2021138761A5 (cg-RX-API-DMAC10.html)
RU98110565A (ru) Новые соединения и их композиции, обладающие противовоспалительной и противотромботической активностями
JP2018511628A5 (cg-RX-API-DMAC10.html)
JP2021533181A5 (cg-RX-API-DMAC10.html)
US20150217005A1 (en) Method for obtaining novel derivatives of naphthalene for the in vivo diagnosis of alzheimer's disease
RU2012149448A (ru) Новые конъюгаты аналогов сс-1065 и бифункциональные линкеры
JP2016516063A5 (cg-RX-API-DMAC10.html)
JP2015501292A5 (cg-RX-API-DMAC10.html)
JP2009523841A5 (cg-RX-API-DMAC10.html)
RU2015125006A (ru) Новые аналоги сс-1065 и их конъюгаты
JP2005539009A5 (cg-RX-API-DMAC10.html)
JP2018516243A5 (cg-RX-API-DMAC10.html)
JP2005533026A5 (cg-RX-API-DMAC10.html)
JP2020534336A5 (cg-RX-API-DMAC10.html)
RU2007121697A (ru) Гидроксибензоатные соли метаникотиновых соединений
GB2614981A (en) Therapeutic cure-pro compounds for targeted degradation of bet domain proteins, and methods of making and using them
RU2005135139A (ru) Медиаторы обратного трансорта холестерина для лечения гиперхолестеринемии
JP2021527064A5 (cg-RX-API-DMAC10.html)